BACKGROUND AND PURPOSE: Inhibition of the renin angiotensin system (RAS) has been consistently demonstrated to reduce atherosclerosis. However, there has been no direct comparison among the three available pharmacological modes of inhibiting the RAS, which are inhibitors of renin, ACE and angiotensin II type 1 receptor. The purpose of this study was to determine the relative effects of these three modes of pharmacological RAS inhibition in reducing atherosclerosis by determining the dose-response relationships. EXPERIMENTAL APPROACH: Male LDL receptor -/- mice were administered either vehicle or any of three doses of aliskiren, enalapril or losartan through s.c. infusion for 12 weeks. All mice were fed a saturated fat-enriched diet during drug infusions. Systolic and diastolic BPs were measured during the study using a non-invasive tail-cuff system. Plasma cholesterol and renin concentrations, atherosclerotic lesions, and renal angiotensin II concentrations were determined at the termination of the study. KEY RESULTS: Plasma renin concentrations were increased by all three drugs. None of the drugs changed plasma cholesterol concentrations. All drugs produced a dose-related decrease in BP. All three drugs also profoundly reduced atherosclerosis in a dose-dependent manner. The highest dose of each drug markedly attenuated lesion size, with no significant differences between the different drugs. The highest dose of each drug also similarly reduced renal angiotensin II concentrations. CONCLUSION AND IMPLICATIONS: Drugs that inhibit the RAS, irrespective of their mode of inhibition, profoundly affect atherosclerotic lesion development in a dose-dependent manner.
BACKGROUND AND PURPOSE: Inhibition of the renin angiotensin system (RAS) has been consistently demonstrated to reduce atherosclerosis. However, there has been no direct comparison among the three available pharmacological modes of inhibiting the RAS, which are inhibitors of renin, ACE and angiotensin II type 1 receptor. The purpose of this study was to determine the relative effects of these three modes of pharmacological RAS inhibition in reducing atherosclerosis by determining the dose-response relationships. EXPERIMENTAL APPROACH: Male LDL receptor -/- mice were administered either vehicle or any of three doses of aliskiren, enalapril or losartan through s.c. infusion for 12 weeks. All mice were fed a saturated fat-enriched diet during drug infusions. Systolic and diastolic BPs were measured during the study using a non-invasive tail-cuff system. Plasma cholesterol and renin concentrations, atherosclerotic lesions, and renal angiotensin II concentrations were determined at the termination of the study. KEY RESULTS: Plasma renin concentrations were increased by all three drugs. None of the drugs changed plasma cholesterol concentrations. All drugs produced a dose-related decrease in BP. All three drugs also profoundly reduced atherosclerosis in a dose-dependent manner. The highest dose of each drug markedly attenuated lesion size, with no significant differences between the different drugs. The highest dose of each drug also similarly reduced renal angiotensin II concentrations. CONCLUSION AND IMPLICATIONS: Drugs that inhibit the RAS, irrespective of their mode of inhibition, profoundly affect atherosclerotic lesion development in a dose-dependent manner.
Authors: Dennis Bruemmer; Alan R Collins; Grace Noh; Wei Wang; Mary Territo; Sarah Arias-Magallona; Michael C Fishbein; Florian Blaschke; Ulrich Kintscher; Kristof Graf; Ronald E Law; Willa A Hsueh Journal: J Clin Invest Date: 2003-11 Impact factor: 14.808
Authors: Riccardo Candido; Karin A Jandeleit-Dahm; Zemin Cao; Stefan P Nesteroff; Wendy C Burns; Stephen M Twigg; Rodney J Dilley; Mark E Cooper; Terri J Allen Journal: Circulation Date: 2002-07-09 Impact factor: 29.690
Authors: Michael T Johnstone; Alexandra S Perez; Imad Nasser; Robert Stewart; Anand Vaidya; Fawaz Al Ammary; Ben Schmidt; Gary Horowitz; Jennifer Dolgoff; James Hamilton; William C Quist Journal: Circulation Date: 2004-09-27 Impact factor: 29.690
Authors: Robson A S Santos; Ana C Simoes e Silva; Christine Maric; Denise M R Silva; Raquel Pillar Machado; Insa de Buhr; Silvia Heringer-Walther; Sergio Veloso B Pinheiro; Myriam Teresa Lopes; Michael Bader; Elizabeth P Mendes; Virgina Soares Lemos; Maria Jose Campagnole-Santos; Heinz-Peter Schultheiss; Robert Speth; Thomas Walther Journal: Proc Natl Acad Sci U S A Date: 2003-06-26 Impact factor: 11.205
Authors: Riccardo Candido; Terri J Allen; Markus Lassila; Zemin Cao; Vicki Thallas; Mark E Cooper; Karin A Jandeleit-Dahm Journal: Circulation Date: 2004-03-15 Impact factor: 29.690
Authors: Xiaofeng Chen; Deborah A Howatt; Anju Balakrishnan; Jessica J Moorleghen; Congqing Wu; Lisa A Cassis; Alan Daugherty; Hong Lu Journal: Arterioscler Thromb Vasc Biol Date: 2016-04-07 Impact factor: 8.311
Authors: Johannes Stegbauer; Sean E Thatcher; Guang Yang; Katharina Bottermann; Lars Christian Rump; Alan Daugherty; Lisa A Cassis Journal: J Vasc Surg Date: 2019-03-06 Impact factor: 4.268
Authors: Hong Lu; Congqing Wu; Deborah A Howatt; Anju Balakrishnan; Jessica J Moorleghen; Xiaofeng Chen; Mingming Zhao; Mark J Graham; Adam E Mullick; Rosanne M Crooke; David L Feldman; Lisa A Cassis; Craig W Vander Kooi; Alan Daugherty Journal: Arterioscler Thromb Vasc Biol Date: 2015-12-17 Impact factor: 8.311
Authors: Robin Shoemaker; Frederique Yiannikouris; Sean Thatcher; Lisa Cassis Journal: Am J Physiol Endocrinol Metab Date: 2015-08-04 Impact factor: 4.310